Delivery Order SPE2DB24D2011-SPE2DB24FBQFV

Award Date 6/25/24
Potential Completion Date 6/26/24
Potential Value $27K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Cosentyx 300 mg dose-2 pen subcutaneous injections to the Defense Logistics Agency (DLA), a component of the Department of Defense. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $7,106.01 and an ultimate completion date of December 22, 2021. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) that...
This federal contract award is for the delivery of Cosentyx 300 mg dose-2 pens to the Defense Logistics Agency (DLA). The $3,136.32 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract has a period of performance through May 25, 2023. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary...
This federal contract award is for the delivery of Cosentyx 300 mg dose-2 pen injectors to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The contract, valued at $1,521.95, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to...
This federal contract award is for the delivery of Cosentyx 300 mg dose-2 pens to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on May 15, 2023 with a ceiling value of $31,694.92 and a completion date of May 16, 2023. The contract is a delivery order under a broader Indefinite Delivery Contract (IDC) that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support...
This federal contract award is for the delivery of Cosentyx (Secukinumab) 300mg dose 2-pen injectors to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on February 6, 2024 with a ceiling value of $5,966.20 and a completion date of February 7, 2024. This is a delivery order contract with a firm fixed price pricing type. The contract does not have a set-aside designation, indicating open competition....
This federal contract award is for the delivery of Cosentyx 300 mg dose injector pens to the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on March 29, 2023, with a ceiling value of $1,696.37 and a completion date of March 30, 2023. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation indicated....
This federal contract award is for the delivery of Cosentyx Unoready 300 mg pen injectors to the Defense Logistics Agency (DLA) Troop Support Medical. The $7,837.91 firm fixed price contract was awarded to prime contractor AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of October 17, 2024. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) held by...
This federal contract award is for the delivery of Cosentyx 300 mg dose-2 syringes to the Defense Logistics Agency (DLA). The $4,052.90 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on November 17, 2022, with a completion date of November 18, 2022. The contract has no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award is to Amerisourcebergen Drug Corp, the Corporate Office division of the pharmaceutical distribution company Amerisourcebergen Corporation, to provide Cosentyx (300 mg) autoinjector pens to the Defense Logistics Agency (DLA). The $15,219.50 firm-fixed-price delivery order, awarded on June 6, 2024, has a completion date of June 28, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with the DLA Troop Support Medical...
This federal contract award is for the delivery of Cosentyx 150 mg/ml syringes to the Defense Logistics Agency (DLA). The contract, valued at $12,175.60, is a firm fixed-price delivery order awarded to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award has an ultimate completion date of September 6, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
  • SPE2DB24D2011
    Indefinite Delivery Contract
  • SPE2DB24D2011-SPE2DB24FBQFV
    Delivery Order

This federal contract award is for the delivery of Cosentyx 300mg dose-2 pen auto-injectors to the Defense Logistics Agency (DLA), a component of the Department of Defense. The $27,420.84 firm fixed-price contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on June 25, 2024 with a completion date of June 26, 2024.

The contract is a delivery order against Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The current award does not have a set-aside designation, indicating open competition.

Generated 5/17/25, 9:44 AM